EBMT 2024 | Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis, MD, PhD, Erasmus MC Cancer Institute, Rotterdam, Netherlands, introduces a genomic classification system that can be used alongside measurable residual disease (MRD) to guide transplant decision-making for patients with acute myeloid leukemia (AML). Dr Versluis recommends that patients with favorable-risk cytogenetics do not always require transplantation, especially those who are MRD-negative. Transplantation should be considered for patients with adverse-risk cytogenetics or patients who remain MRD-positive after induction treatment. For patients with intermediate-risk cytogenetics, MRD levels should be used to guide transplant decisions. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
